These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 30093883)

  • 1. The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity.
    Wan N; Rahman A; Hitomi H; Nishiyama A
    Front Endocrinol (Lausanne); 2018; 9():421. PubMed ID: 30093883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
    Lee S
    Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.
    Cavaiola TS; Pettus J
    Diabetes Metab Syndr Obes; 2018; 11():133-148. PubMed ID: 29695924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure.
    Rahman A; Hitomi H; Nishiyama A
    Hypertens Res; 2017 Jun; 40(6):535-540. PubMed ID: 28100918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review.
    Rastogi A; Bhansali A
    Diabetes Ther; 2017 Dec; 8(6):1245-1251. PubMed ID: 29076040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World Data.
    Gallwitz B
    Eur Endocrinol; 2018 Apr; 14(1):17-23. PubMed ID: 29922347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.
    Marx N; McGuire DK
    Eur Heart J; 2016 Nov; 37(42):3192-3200. PubMed ID: 27153861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleiotropic effects of SGLT2 inhibitors beyond the effect on glycemic control.
    Satoh H
    Diabetol Int; 2018 Oct; 9(4):212-214. PubMed ID: 30603370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
    Scheen AJ; Delanaye P
    Diabetes Metab; 2017 Apr; 43(2):99-109. PubMed ID: 28153377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
    Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
    Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of an SGLT2 inhibitor on the salt sensitivity of blood pressure and sympathetic nerve activity in a nondiabetic rat model of chronic kidney disease.
    Wan N; Fujisawa Y; Kobara H; Masaki T; Nakano D; Rahman A; Nishiyama A
    Hypertens Res; 2020 Jun; 43(6):492-499. PubMed ID: 32060381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
    Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
    Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome.
    Rahman A; Kittikulsuth W; Fujisawa Y; Sufiun A; Rafiq K; Hitomi H; Nakano D; Sohara E; Uchida S; Nishiyama A
    J Hypertens; 2016 May; 34(5):893-906. PubMed ID: 26982381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes?
    Saisho Y
    Diseases; 2020 May; 8(2):. PubMed ID: 32403420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.
    Scheen AJ
    Diabetes Metab; 2016 Sep; 42(4):224-33. PubMed ID: 27291329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of EMPA-REG OUTCOME
    Naing S; Poliyedath A; Khandelwal S; Sigala T
    Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus.
    Tang H; Fang Z; Wang T; Cui W; Zhai S; Song Y
    Am J Cardiol; 2016 Dec; 118(11):1774-1780. PubMed ID: 27666177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats.
    Takeshige Y; Fujisawa Y; Rahman A; Kittikulsuth W; Nakano D; Mori H; Masaki T; Ohmori K; Kohno M; Ogata H; Nishiyama A
    Hypertens Res; 2016 Jun; 39(6):415-22. PubMed ID: 26818652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
    Chrysant SG
    Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.